Skip to main content

Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma will go public soon. The estimated IPO date is December 1, 2021.
Stock Price: $12.00 - $14.00
Current IPO price range

Company Description

Nuvectis Pharma is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology.

We rely on our core competencies of target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs.

Improved genetic sequencing and understanding of cancers’ RNA, DNA and protein abnormalities has led to the discovery and characterization of novel oncogenic genetic mutations and alterations that were previously unknown, unaddressed, unsuccessfully targeted or overlooked.

We believe that these advancements represent a fundamental change in the development of targeted therapies and will increasingly lead to tumor agnostic approaches whereby cancers will be characterized for treatment based on genetic signatures, such as a certain mutation, rather than in a tissue-specific manner.

We are currently developing two preclinical drug candidates with the lead candidate expected to begin a Phase 1 clinical trial in the fourth quarter of 2021.

Nuvectis Pharma, Inc.
CountryUnited States
Founded2020
IPO DateDec 1, 2021
IndustryBiotechnology
SectorHealth Care
Employees3
CEORon Bentsur, M.B.A.

Contact Details

Address:
1 Bridge Plaza, Suite 275
Fort Lee, NJ 07024
United States
Phone(201) 614-3150
Websitenuvectis.com

Stock Details

Ticker SymbolNVCT
ExchangeNASDAQ
Reporting CurrencyUS Dollars
CIK Code1875558

Key Executives

NamePosition
Ron BentsurChairman, Chief Executive Officer and President
Enrique PoradosuExecutive Vice President, Chief Scientific and Business Officer
Shay ShemeshExecutive Vice President, Chief Development Officer
Uri Ben-OrInterim Chief Financial Officer, Consultant
Kenneth HobermanDirector
Matthew KaplanDirector
James F. OlivieroDirector

Latest SEC Filings

DateTypeTitle
Nov 9, 2021FWPFiling under Securities Act Rules 163/433 of free writing prospectuses
Nov 8, 2021S-1/AGeneral form for registration of securities under the Securities Act of 1933
Nov 4, 2021FWPFiling under Securities Act Rules 163/433 of free writing prospectuses
Nov 2, 2021FWPFiling under Securities Act Rules 163/433 of free writing prospectuses
Oct 29, 2021D/ANotice of Exempt Offering of Securities
Oct 28, 2021S-1/AGeneral form for registration of securities under the Securities Act of 1933
Oct 20, 2021S-1/AGeneral form for registration of securities under the Securities Act of 1933
Oct 6, 2021S-1General form for registration of securities under the Securities Act of 1933
Sep 20, 2021DRS/ADraft Registration Statement
Jul 30, 2021DRSDraft Registration Statement
View All SEC Filings